Growth Metrics

Biogen (BIIB) EBIT Margin (2016 - 2026)

Biogen has reported EBIT Margin over the past 18 years, most recently at 11.43% for Q1 2026.

  • For Q1 2026, EBIT Margin rose 165.0% year-over-year to 11.43%; the TTM value through Mar 2026 reached 8.18%, down 161.0%, while the annual FY2025 figure was 8.57%, 439.0% down from the prior year.
  • EBIT Margin for Q1 2026 was 11.43% at Biogen, up from 24.19% in the prior quarter.
  • Over five years, EBIT Margin peaked at 35.94% in Q3 2022 and troughed at 31.65% in Q3 2023.
  • A 5-year average of 0.72% and a median of 3.38% in 2024 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: crashed -6759bps in 2023 and later surged 2404bps in 2024.
  • Year by year, EBIT Margin stood at 17.29% in 2022, then plummeted by -69bps to 5.35% in 2023, then tumbled by -322bps to 11.9% in 2024, then plummeted by -103bps to 24.19% in 2025, then surged by 53bps to 11.43% in 2026.
  • Business Quant data shows EBIT Margin for BIIB at 11.43% in Q1 2026, 24.19% in Q4 2025, and 4.62% in Q3 2025.